Skip to main content
Log in

Drug Treatment of Phobias

Efficacy and Optimum Use

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

In the last decade anxiety disorders have been the focus of intensive research in the psychiatric community, resulting in a rapid growth in our understanding of these illnesses. Diagnostic, biological, and psychopharmacological investigations have revealed important distinctions among these disorders which enable the clinician to make well- informed therapeutic choices and frequently ameliorate or even eliminate anxiety symptoms and related phobic behaviour. The principles of treatment can be simply stated:

  1. 1.

    Careful diagnostic evaluation through history and exclusion of medical and psychiatric conditions which mimic anxiety disorders.

  2. 2.

    Treatment selection based on diagnosis and formulation with the patient of the goals and expected outcome of pharmacotherapy.

  3. 3.

    Systematic application of each drug treatment in sufficient dosage and for an adequate duration permitting progression to the next agent when results are not optimal.

  4. 4.

    Addition of non- pharmacological interventions, usually behavioural therapy, to decrease phobic behaviour.

  5. 5.

    Development of a maintenance or discontinuation strategy tailored to the needs of the patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Brier A, Charney DS, Nelson JC. Seizures induced by abrupt withdrawal of alprazolam. American Journal of Psychiatry 141: 1606–1607, 1984

    Google Scholar 

  • Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. Journal of Clinical Psychopharmacology 46: 206–209, 1985

    CAS  Google Scholar 

  • Gorman JM, Fyer AJ, Gliklich J, et al. Mitral valve prolapse and panic disorders: effects of imipramine. In Klein et al. (Eds) Anxiety — new research and changing concepts, Raven Press, New York, 1981

    Google Scholar 

  • Gorman JM, Levy GF, Liebowitz MR, et al. Effect of acute beta-adrenergic blockade on lactate-induced panic. Archives of General Psychiatry 40: 1079–1083, 1984a

    Article  Google Scholar 

  • Gorman JM, Liebowitz MR, Fyer AJ, et al. Treatment of social phobia with atenolol. Journal of Clinical Psychopharmacology 5: 298–301, 1985

    Article  PubMed  CAS  Google Scholar 

  • Gorman JM, Martinez JM, Liebowitz MR, et al. Hypoglycemia and panic attacks. American Journal of Psychiatry 141: 101–104, 1984b

    PubMed  CAS  Google Scholar 

  • Insel TR, Hamilton JA, Guttmacher LB, et al. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology 80: 231–235, 1983

    Article  PubMed  CAS  Google Scholar 

  • Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5: 397–408, 1964

    Article  PubMed  CAS  Google Scholar 

  • Klein DF. Anxiety reconceptualized. In Klein et al. (Eds) Anxiety — new research and changing concepts, Raven Press, New York, 1981

    Google Scholar 

  • Liebowitz MR, Gorman JM, Fyer AJ, et al. Social phobia: review of a neglected disorder. Archives of General Psychiatry 42: 729–736, 1985

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine versus impramine in atypical depression. Archives of General Psychiatry 41: 669–677, 1984

    Article  PubMed  CAS  Google Scholar 

  • Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals. British Journal of Psychiatry 136: 1–25, 1980

    Article  PubMed  CAS  Google Scholar 

  • Noyes R, Anderson DJ, Clancy J, et al. Diazepam and propranolol in panic disorder and agoraphobia. Archives of General Psychiatry 41: 287–292, 1984

    Article  PubMed  Google Scholar 

  • Shader RI, Greenblatt DJ. Editorial. Journal of Clinical Psychopharmacology 4: 1, 1984

    Article  Google Scholar 

  • Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Archives of General Psychiatry 37: 51–59, 1980

    Article  PubMed  CAS  Google Scholar 

  • Sheehan DV, Coleman JH, Greenblatt DJ, et al. Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. Journal of Clinical Psychopharmacology 4: 66–75, 1984

    Article  PubMed  CAS  Google Scholar 

  • Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled trial. Archives of General Psychiatry 37: 1381–1385, 1980

    Article  Google Scholar 

  • Uhde TW, Vittone BJ, Post RM. Glucose tolerance testing in panic disorder. American Journal of Psychiatry 141: 1461–1463, 1984

    PubMed  CAS  Google Scholar 

  • White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. Journal of Clinical Psychopharmacology 1: 264–282, 1981

    Article  PubMed  CAS  Google Scholar 

  • Zitrin CM, Klein DF, Woerner MG, et al. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Archives of General Psychiatry 40: 125–138, 1983

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levin, A.P., Liebowitz, M.R. Drug Treatment of Phobias. Drugs 34, 504–514 (1987). https://doi.org/10.2165/00003495-198734040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198734040-00004

Keywords

Navigation